

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511. Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Ref: Corp.Sec/2024-25/305

Dated: 19.02.2025

To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001

SCRIPT CODE: 524703

Dear Sir/Ma'am,

<u>Sub: Our Clarification to Your Email dated 18.02.2025 on Non-compliance with Regulation 33</u> of SEBI (LODR) Regulations, 2015 for the period ended December 31, 2024.

Ref: Exchange communication dated 18th February 2025 towards Non submission of Consolidated unaudited Financial Results for Q ended 31.12.2024.

This is to inform you that Board of Directors of M/s Sandu Pharmaceuticals Limited at its Meeting held on 30th May 2024, has approved sale of investment (sale of Equity Shares) in M/s Sandu Phytoceuticals Private Limited its wholly owned subsidiary–(Non Material subsidiary), the necessary disclosure under Regulation 30 pertaining to sale of investment in the prescribed format has been submitted to exchange on 30th May 2024. Attaching herewith the copy submission made for the reference.

Further we would like to inform you that Sandu Phytoceuticals Private Limited was non material subsidiary of M/s Sandu Pharmaceuticals Limited pursuant to Regulation 30 Schedule III Part A point 1 but disclosure under regulation 30 after Board Meeting dated 30th May 2024 was made by the Company, reproducing herewith disclosure made Regulation 30 of the SEBI (LODR) after Board Meeting dated 30th May 2024 again for your reference .we further wish to inform you that the data submitted on 30th May 2024 remains unchanged/Unaltered.

Regulation 30 Part A POINT 1-M/s Sandu Phytoceuticals Private Limited was not Material Subsidiary as it was not fulfilling the condition mentioned under section 180 of the Companies Act 2013.

1. [Acquisition(s) (including agreement to acquire), Scheme of Arrangement (amalgamation, merger, demerger or restructuring), sale or disposal of any unit(s), division(s), whole or substantially the whole of the undertaking(s) or subsidiary of the listed entity, sale of stake in associate company of the listed entity or any other restructuring.

Explanation (2) - For the purpose of this sub-paragraph, "sale or disposal of subsidiary" and "sale of stake in associate company" shall include-

- (i) an agreement to sell or sale of shares or voting rights in a company such that the company ceases to be a wholly owned subsidiary, a subsidiary or an associate company of the listed entity; or
- (ii) an agreement to sell or sale of shares or voting rights in a subsidiary or associate company such that the amount of the sale exceeds the threshold specified in sub-clause (c) of clause (i) of sub-regulation (4) of regulation 30.







CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511. Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Explanation (3)- For the purpose of this sub-paragraph, "undertaking" and "substantially the whole of the undertaking" shall have the same meaning as given under section 180 of the Companies Act, 2013.]

As per information received from M/s Sandu Phytoceuticals Private Limited there was no Board Meeting held between dates 30th May 2024 till 10th August 2024.

The share transfer requests were taken up for discussion and approved by Board of Directors of Sandu Phytoceuticals Private Limited in the Board Meeting held on 10th August 2024.

Shares were transferred in the individual capacity in favour of Shri Umesh B Sandu (DIN:01132141) and Shri Shashank B Sandu (DIN:00678098) as per the valuation report issued by CA Murli Chandak, IBBI Registered Valuer of Securities and financial assets dated 28th May 2024.

The Company had duly filed Consolidated Financials for the Quarter ended 30th September 2024. For the Quarter ended 31st December 2024 Company did not have any subsidiary company so no consolidation was required.

We would also like to bring to your kind notice that, intimation was also given to The exchange about non applicability of consolidation while giving intimation about dates of the Board Meeting and also in the outcome of the Board Meeting.

Requesting you to kindly take a note of the above clarification on record and close the discrepancy.

Thanking you,

Yours faithfully, For. Sandu Pharmaceuticals Limited



Pratika Mhambray
Company Secretary and Compliance Officer
A36512

Encl.:As Above







CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511. Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with along with SEBI circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13,2023.

<u>Sr No</u>	<u>Particulars</u>	<u>Details</u>
a)	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associates company of	Turnover of Sandu Phytoceuticals Private Limited as on 31st March 2023 is Rs 0 constituting 0 % to consolidated income. Net Worth as on 31 March 2023 is INR
	the listed entity during the last financial year	72725 constituting 0.00 % to Net Worth
b)	Date on which the agreement for sale has been entered into	NA
с)	The expected date of completion of sale/disposal	The sale will be concluded once the transfer of shares is approved by the Board of Directors of Sandu Phytoceuticals Private Limited and shares are transferred from Sandu Pharmaceuticals Limited to Shri Umesh Sandu (50%) and Shri Shashank Sandu (50%) vide share transfer form. The total consideration amount payable
		for Transfer of Shares will be Rs 66700/-
d)	Consideration received from such sale/disposal	The Company has no revenues for the last year and only has costs in its Profit and Loss and therefore incurring losses. Sandu Phytoceuticals has no plans to add any activity to this company and to reduce all administrative and related costs, the company's shareholding is being sold. We have obtained a valuation from an authorized registered valuer and the Board Approval has been taken on 30th May 2024. The Consideration of the shares is fixed at .Rs 66700/-
		The consideration Amount of Rs 33350 will be paid by Shri Umesh Sandu and Rs 33350 will be paid by Shri Shashank Sandu.
e)	Brief details of buyers and whether any of the buyer belong to the Promoter/Promoter Group	Shri Umesh Sandu and Shri Shashank Sandu.
	companies. If yes details thereof	Shri. Umesh Sandu(DIN:01132141) is Managing Director and Promoter in Sandu Pharmaceuticals Limited holding 13,88,693 Equity Shares.
		Shri. Shashank Sandu (DIN: 00678098) is Non Executive Director and Promoter in Sandu Pharmaceuticals Limited holding 13,68,755 Equity Shares.







CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511. Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

		Yes They Belong to Promoter Group
f)	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm length"	
g)	Whether the sale, lease or disposal of the undertaking is outside scheme of arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulation.	NA
h)	Additionally, in case of a slump sale, indicative disclosure provided for amalgamation/merger, shall be disclosed by the Listed entity with respect to such slump sale	

Yours faithfully, For. Sandu Pharmaceuticals Limited

Pratika Mhambray Company Secretary and Compliance Officer A36512









CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511. Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Encl.:As Above







IN:L24233GA1965PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Ref: SPL/CORP-SEC/2024-25/BSE/187

Dated:30.05.2024

To, Bombay Stock Exchange Ltd, Phirojshah Jeejobhoy Towers, 25th Floor, Dalal Street, Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

Sub: Outcome of the Board Meeting with Scrip Code 524703.

A Meeting of the Board of Directors of the Company duly convened on Thursday, 30th May 2024 at 05:00 p.m. and concluded at 10.40 p.m. discussed the following business: -

- Re-Appointment of, CMA Shekhar Joshi & Co Cost Accountants, having firm Registration No. 100448 as the Cost Auditors of the Company for the financial year 2024-25.
- Considered and approved sale of 100% investments in Sandu Phytoceuticals Private Limited ,Wholly owned Subsidiary of Sandu Pharmaceuticals Limited. Shares to be sold to Shri Umesh Sandu Promoter of Sandu Pharmaceuticals Limited and Shri Shashank Sandu Promoter of Sandu Pharmaceuticals Limited for consideration amount of Rs 66700/- (Sixty Six Thousand Seven Hundered only) as per the valuation Report issued by CA Murli Chandak, IBBI Registered valuer of Securities and financial assets dated 28TH May 2024.

Further we would like to inform that Standalone and Consolidated Financials for Quarter and Year ended 31st March 2024 could not be uploaded as Chief Financial Officer Shri Vijay Kajrekar was appointed only on 30st March 2024 as required under regulation 33 of SEBI(listing Obligation and Disclosure Requirement)Regulation 2015.

Further, in this connection and in continuation of our letter dated 16.03.2024 the Trading Window for dealing in the equity shares of the Company had been closed from 01st April 2024 and will continue to remain closed till 48 hours after the date of declaration of audited Financial Results for the quarter / year ended 31st March 2024, pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and Company's Code for prohibition of Insider Trading. The date of the Board Meeting for the aforesaid purpose i.e Finalisation of Financials shall be intimated separately after finalizing the same.

Details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed as Annexure A and Annexure B.







CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511. Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

You are requested to kindly take the same on record.

Yours Faithfully,


FOR SANDU PHARMACEUTICALS LTD.

PRATIKA Digitally signed by PRATIKA PRATHAMESH MHAMBRAY Date: 2024-05-30 MHAMBRAY 22-39-18 4 05°30

Pratika Mhambray Company Secretary











CIN-L 24233GA 1985PL C001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511. Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Annexure A

Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with along with SEBI circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13,2023


<u>Sr No</u>	<u>Particulars</u>	Cost Auditor Shekhar Joshi & Co
1.	Reason for change viz. appointment, resignation, removal dealth or otherwise	Reappointment
2.	Date of appointment/cessation (as applicable)& term of appointment	Date of Reappointment 30.05.2024 Term of appointment: Financial Year 2024-25
3.	Brief Profile (incase of appointment)	Shekhar Joshi is M.Com, LL.B, FCMA, M.B.A. with 35 plus years of experience.He is Visiting Faculty at The ICFAI Business School, Sterling Institute of Management, The Atharva Institute of Management Studies, Finplan Institute and Institute of Cost Accountants of India Areas of Specialization Cost Audit• Management Consultancy• Statutory Compliances• Business Valuation for Banking and Take Over• Assisting Mergers and Acquisitions• Due Diligence• Project Appraisal and Evaluation• Internal and MIS systems• Stock Audits• Product Costing• Market Profitability Analysis. Projects Handled Cost Audit and Cost Compliances• Implementation of Costing Systems• Due Diligence• Feasibility study of Merger• Corporate Valuations• MIS Implementation• Costing MIS and Routine Assistance• Budgets and Follow ups

Annexure B

Sr No	Particulars	Details
a)	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associates company of the listed entity during the last financial year	Turnover of Sandu Phytoceuticals Private Limited as on 31 st March 2023 is Rs 0 constituting 0 % to consolidated income. Net Worth as on 31 March 2023 is INR 72725 constituting 0.00 % to Net Worth
b)	Date on which the agreement for sale has been entered into	NA
c)	The expected date of completion of sale/disposal	The sale will be concluded once the transfer of shares is approved by the Board of Directors of Sandu Phytoceuticals Private Limited and shares are transferred from Sandu Pharmaceuticals Limited to Shri Umesh Sandu (50%) and Shri Shashank Sandu (50%) vide share transfer form.











CIN:L24233GA1985PLC001587

Regd. Office: Piot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511. Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

		The total consideration amount payable for Transfer of Shares will be Rs 66700/-
d)	Consideration received from such sale/disposal	The Company has no revenues for the last year and only has costs in its Profit and Loss and therefore incurring losses. Sandu Phytoceuticals has no plans to add any activity to this company and to reduce all administrative and related costs, the company's shareholding is being sold. We have obtained a valuation from an authorized registered valuer and the Board Approval has been taken on 30 th May 2024. The Consideration of the shares is fixed at .Rs 66700/-
		The consideration Amount of Rs 33350 will be paid by Shri Umesh Sandu and Rs 33350 will be paid by Shri Shashank Sandu.
e)	Brief details of buyers and whether any of the buyer belong to the Promoter/Promoter Group companies. If yes details thereof	Shri Umesh Sandu and Shri Shashank Sandu. Shri. Umesh Sandu(DIN:01132141) is Managing Director and Promoter in Sandu Pharmaceuticals Limited holding 13,88,693 Equity Shares. Shri. Shashank Sandu (DIN: 00678098) is Non Executive Director and Promoter in Sandu Pharmaceuticals Limited holding 13,68,755 Equity Shares.
		Yes They Belong to Promoter Group
f)	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm length"	Yes The Transactions with Shri Umesh B Sandu and Shri Shashank B Sandu is falling under related party transaction and is on arm length Basis However, the sale price will be the same as being sold to a "non related party"
g)	Whether the sale, lease or disposal of the undertaking is outside scheme of arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulation.	NA
h)	Additionally, in case of a slump sale, indicative disclosure provided for amalgamation/merger, shall be disclosed by the Listed entity with respect to such slump sale	NA







Regd. Office: Plot Nos. 25, 26, 29 & 30, Pileme Industrial Estate, Marra, Saligao, Bardez, Goa 403511. Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

FOR SANDU PHARMACEUTICALS LTD.

PRATIKA

Digitally signed by PRATIKA PRATHAMESH

PRATHAMESH MHAMBRAY MHAMBRAY

Date: 2024.05.30 22:39:39 +05'30'

Pratika Mhambray Company Secretary





